glp-1 intestinal paralysis attorney in kentucky dallas semaglutide semaglutide intestinal paralysis lawyer kentucky semaglutide gastrointestinal obstruction lawyer Semaglutide Claim Eligibility for Injured Consumers kentucky glp-1 intestinal paralysis legal

396.Li, H

Digestive Adjustments Your digestive system is adapting

10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments

For many in the UK, these medications are prescribed via the NHS or private clinics for obesity management or type 2 diabetes

World Health Organization, Obesity and overweight. June 9, 2021

If you are comparing your options, our semaglutide side effects guide is a helpful place to start